Investorideas.com - Arizona's Largest Dispensary Continues To Grow With New Locations And Expanded Offerings
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Friday, September 4, 2020
Thursday, September 3, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 463 (TSX: $LABS.TO) (CSE: $PLUS.C) (CSE: $THC.C)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 463 (TSX: $LABS.TO) (CSE: $PLUS.C) (CSE: $THC.C)
Delta, Kelowna, BC, September 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/090320-StocksToWatch.mp3
Read this news in full at https://www.investorideas.com/news/2020/cannabis-potcasts/09031LABS-PLUS-THC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Reformulary Group, an expert-led healthcare company that helps Canadians make sense of medicine (prescription drugs and medical cannabis, announced the launch of its Cannabis Standard™ Index. The Index uniformly categorizes medical cannabis products based on objective data, allowing Canadians and the medical community to find accurate, detailed information and to reliably search and compare products.
"We want to help patients, and their doctors make sense of medical cannabis, so we worked with a group of experts to develop a standardized classification system as is the norm with prescription and over-the-counter drugs, but designed explicitly for cannabinoid-based medicine," said Helen Stevenson, founder and CEO of Reformulary Group. "The Cannabis Standard Index makes it possible for patients and healthcare professionals to search and compare cannabis products and to determine which are similar or interchangeable."
The Index is an educational tool that allows medical cannabis patients and their doctors to assess and compare products made by different Licensed Producers (LPs) using objective data such as composition, format and form rather than strain name. As there are no industry standards for the naming of strains, some producers may apply strain names to products with different concentrations of cannabinoids. By indexing products using objective data, including the presence of major (THC, CBD) and minor cannabinoids (THCA, CBDA, CBG, CBC, CBN) where the information is available, the Index can help guide reliable prescribing and therapeutic substitutions. So, when a medical cannabis patient seeks a change in product type or when a patient's usual LP runs out of stock, they can find an effective alternative.
A national study conducted by RIWI Corp., a global trend-tracking and prediction technology firm, in summer 2019 revealed that two-thirds of medical cannabis patients were interested in a rating system that categorizes cannabis into product types and helps consumers compare products.
[New study underscores importance of medical cannabis rating system: https://reformulary.com/news/new-study-underscores-importance-of-medical-cannabis-rating-system]
The Index is the latest addition to Cannabis Standard, an ecosystem of expert recommendations, patient-powered tools, and independent information to help Canadians and healthcare professionals make smarter, more informed decisions about medical cannabis.
"The addition of the Index to the Cannabis Standard ecosystem empowers patients and healthcare practitioners to access and evaluate medical cannabis with the same level of sophistication as with prescription drugs," said Dr. Alan Bell, family physician and Assistant Professor in the Department of Family and Community Medicine at the University of Toronto.
"Rather than relying on a product strain name, or user-generated reviews, we now have a system to help categorize and differentiate medical cannabis using data relevant for doctors and patients," he added."When medicine makes sense, we all benefit," said Ms. Stevenson, who is the former Assistant Deputy Minister of Health in Ontario. In this role, she ran Ontario's $4 billion drug program, overseeing the Ontario Drug Benefit Formulary. The Cannabis Index borrows from some of the same principles as Reformulary's award-winning DrugFinder™ tool. DrugFinder is broadly offered by Canadian employers to their plan members, and provides patients and plan members with evidence-based information about their medication, empowering them to make informed choices.
The Cannabis Standard Index is free and open source. Reformulary Group endeavors to include products from as many licensed producers as possible. It does not sell cannabis, receives no commissions and does not benefit from the sale of medical cannabis.
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) today announced that its wholly owned subsidiary MediPharm Labs Inc. will supply premium, formulated cannabis oil to Cann Farm Peru S.A.C., a Lima-based producer and distributor serving Peruvian and other markets in Latin America.
This is MediPharm Labs first such agreement in Latin America and the most recent example of the Company’s international growth strategy in action. As part of this strategy, the Company has expanded its addressable medical, wellness and adult-use markets to parts of Asia Pacific, Europe and now Latin America.
MediPharm Labs is creating footholds in medical, wellness and adult-use markets around the world and in Latin American countries. With a combined population of approximately 580 million - and beginning with its fifth largest country Peru – Latin America factors highly in the Company’s business plan. As an early mover among Latin American countries, Peru has created a legal framework for producing, importing and selling cannabis for medical use. As a result, Peru’s market is advancing rapidly and offers the potential to register varied formats of cannabis based products. Using a range of pricing, consumption and patient datasets, the LATAM Cannabis Report™ by Prohibition Partners(1) forecasts that the LATAM market is expected to exceed US$12 billion by 2028, offering “serious growth potential to global cannabis companies.”
“Peru is one of the top medical cannabis markets in the world and Cann Farm is one of very few cannabis companies which hold both a DroguerÃa licence and cannabis importation licence which makes this agreement of outstanding strategic value to MediPharm Labs,” said Pat McCutcheon, CEO, MediPharm Labs. “As we pursue our global ambitions, it is vital for us to partner with companies of Cann Farm’s calibre who know their local markets intimately, have a real appreciation for the needs of patients, an ongoing commitment to scientific advancement and a sound plan for regional expansion. We expect great things from this collaboration.”
Under the one-year renewable agreement, MediPharm Labs Inc. will provide a variety of cannabis concentrate formats, with optionality for patient ready formulated products. The products will be distributed to patients through pharmacies in Peru. Cann Farm will in turn obtain all Peruvian registrations, authorizations and approvals required for importation. In the future, Cann Farm may look to MediPharm Labs for further support in commercialization activities. MediPharm Labs anticipates delivery to begin in Q4 2020, pending regulatory approval by applicable health authorities.
“Cann Farm was created from our deep commitment to patients, who demand reliable, consistent high quality, and proven product integrity; therefore we choose our partners very carefully,” said Andres Vazquez Vargas, Executive President, Cann Farm Peru. “What impresses us most about MediPharm Labs is their focus on medical markets and their commitment to our production standards, as is seen with their GMP certification, which is the gold standard in pharma production. It’s rare to see GMP certification in the cannabis supply chain because it’s a complex and rigorous process to earn the qualification. This tells us all we need to know about their ability to meet our needs on not only a continuous, but consistent basis.”
Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) today announced the launch of its new PLUS SLEEP brand into the California adult-use market.
Highlights
● 4 key ingredients to promote a well-rounded night of sleep: THC, CBN, CBD, and just a touch of melatonin.
● All-natural colors and flavors, with only 0.7g of sugar and 5 calories per gummy.
● 2 formulations to offer multiple potential solutions to a wide range of consumers: Sleep Cloudberry, with 5mg of THC, 1mg of CBN, and 1mg of CBD, along with CBNRelief Lychee, with 1mg of THC, 2mg of CBN, and 3mg of CBD.
PLUS’s new SLEEP gummies are scientifically formulated with a precise blend of cannabinoids and melatonin intended to help consumers fall asleep quickly and enjoy a full, restful night’s sleep.
Recent research on the interaction between cannabis, the endocannabinoid system, and the body’s natural circadian rhythm¹ drove PLUS’s formulations of the two new SLEEP products. “Each cannabinoid was selected for how it promotes better sleep, but together they have the potential to be greater than the sum of their parts. This is often referred to as the entourage effect.2 We also included a physiologic dose of melatonin to support our bodies’ circadian rhythm, so these gummies actually work in concert with our natural systems,” stated Dr. Ari Mackler, Chief Scientific Officer.
“We’re excited to help the 71% of cannabis sleep aid users who are not satisfied with their current remedies3,” stated Jake Heimark, CEO and Co-Founder. “Almost 50 million people in the US suffer from insomnia.4 It’s no surprise we hear all the time that one of the top things people look for when they walk into a licensed retailer is something to help them sleep.”
THC BioMed Intl Ltd. (CSE:THC) announced that it has shipped its "Ready to Drink" Cannabis Beverage Shot, THC KISS, to the Ontario Cannabis Store. OCS is the only legal online retailer of recreational cannabis in Ontario.
THC Kiss is also available for purchase in B.C. and Saskatchewan. THC BioMed is in discussion with other provinces to widen its distribution.
THC KISS is a breakthrough Cannabis Beverage Shot that promises to offer a different experience compared to edibles and beverages currently available in either the grey or legal cannabis markets.
THC Kiss aims to be an alternative to smoking cannabis and was developed by THC BioMed using proprietary extraction methods invented by THC BioMed.
"We are proud to bring Canadians a true alternative to smoking cannabis," commented John Miller, president and CEO.
"We continue to receive very positive feedback from consumers. We have received many requests that indicate a high demand for our current products and those in development. THC BioMed continues to deliver a wide array of cannabis products to cater for all classes of cannabis consumers. In addition, all of our products are developed, manufactured and packaged by THC BioMed itself," said Mr. Miller.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Wednesday, September 2, 2020
Investorideas.com - Marijuana Use Growing in Popularity Among Seniors
Investorideas.com - Marijuana Use Growing in Popularity Among Seniors
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Tuesday, September 1, 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 462 (CSE: $GTII.C) (OTCQB: $MGWFF)(CSE: $CURA.C) (NASDAQ: $AMRS)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 462 (CSE: $GTII.C) (OTCQB: $MGWFF)(CSE: $CURA.C) (NASDAQ: $AMRS)
Delta, Kelowna, BC, September 1, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/090120-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/09011GTII-MGWFF-CURA-AMRS.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ and Essence retail stores, today announced that the company has partnered with Last Prisoner Project (LPP) on an integrated marketing campaign, including a short documentary, social media advocacy, digital promotions and in-store programs to raise awareness and funds for LPP’s important work.
LPP is a coalition of cannabis industry leaders, executives and artists dedicated to bringing restorative justice to the cannabis industry. The organization’s Clemency and Reentry Initiatives provide pro-bono post-conviction representation to assist individuals in securing release and a clean slate to rebuild their lives.
The centerpiece of the campaign is a short documentary, “Waiting to Breathe,” created in-house by Green Thumb. The film highlights the story of Evelyn LaChapelle, a current LPP Advisor who served more than five years in prison for a cannabis-related offense and has since rebuilt her life with her young daughter with support from LPP.
Following her release, LaChapelle was fired from a job when the company learned about her past. “When I got fired it was like you aren’t done serving your sentence,” said LaChapelle, who currently works in the legal cannabis industry in California. “It was like this is never going to go away. It leaves you with an amount of hopelessness.”
Sarah Gersten, Executive Director and General Counsel of LPP said: “Evelyn’s story really moved all of us and changed the way we envisioned this project and our mission. All of the barriers she faced coming out of prison, how difficult it was for her to find employment, watching her struggle through all of that really gave us the insight to refocus our efforts, not just on releasing folks from incarceration but working with them to ensure that they have the resources they need to successfully reenter.”
According to various sources:
● An estimated 40,000 people are currently incarcerated for victimless cannabis offenses. (Source: LPP)
● 92 percent of 663,367 cannabis arrests in 2018 were for possession alone. (Source: FBI Uniform Crime Reporting Program, 2018)
● Black people are 3.64 times more likely than white people to be arrested for cannabis possession yet are no more likely to sell or use cannabis. (Source: ACLU)
A portion of proceeds from Green Thumb products purchased in the month of September will directly benefit LPP.
Green Thumb Corporate Social Responsibility Director Michael Fields said: “By partnering with LPP, Green Thumb hopes to raise awareness of real people like Evelyn whose lives and families have been positively impacted by LPP, and to provide financial support to LPP which serves as a vital resource for former cannabis inmates transitioning to a successful life following incarceration.”
Maple Leaf Green World Inc. (NEO: MGW) (OTCQB: MGWFF) provided the following update for its California CBG Hemp Project. A sample from a selective batch of La Cr̬me from the first 2 greenhouses which is 2 Р4 weeks from full maturity, has been submitted for lab analysis and the results indicate an incredible 13.90% CBG, 0.07% THC and no other cannabinoids detected. It is noteworthy that most samples would present traces of other cannabinoids as enzymes break down CBGa to produce other cannabinoids. The lack of these other cannabinoids indicates a pure CBG flower.
The plants have been kept longer in the vegetative stage deliberately to develop larger buds and higher poundage. The low THC nature of the La Cr̬me strain has allowed the Company to make adjustments during the vegetative phase to maximize both CBG concentration and yield. These plants will be ready for harvesting within the next 2 Р4 weeks.
The outdoor crop is also displaying numerous large buds and is estimated to produce 2 – 3 lbs of flower per plant. The Company’s cultivation team is excited with the early results and is confident that the flowers, when fully mature, will achieve a minimum of 18% CBG. As the Company prepares for its first harvest, clones have also been cut and setup for the 2nd harvest.
The preliminary Certificate of Analysis (“COA”) has been posted to the company’s website.
“I am very impressed with the purity of our first harvest. The low THC nature of this strain gave us the flexibility to extend the length of our vegetating stage to obtain higher CBG content and larger buds without the risk of our harvest going hot. This will be resulted in approximately 30-40% increase in yield. We are excited to see the final results from a fully mature flower.” said Raymond Lai, Chairman, President & CEO
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading vertically integrated cannabis operator in the United States, today announced that its line of Select Elite Live cartridges has reached $1 million in sales since launching in the Florida medical market on August 6.
Select Elite Live features high quality, high potency oil with a wide variety of strain-specific flavor and effects. Curaleaf will unveil additional Select product offerings to Florida's medical patients later this year, including the best-selling high potency broad spectrum Select Elite cartridges. As a recognized industry leader, Select is committed to maintaining the highest quality control standards and testing transparency and delivering the best experience possible.
"We are thrilled to have received such a positive response to Elite Live from our Florida patients, and look forward to continuing to provide innovative new products for their cannabis needs," said Joe Bayern, President of Curaleaf. "The immediate success of Elite Live in Florida speaks to the power of the Select brand, and we are confident about our continued growth in the state."
Select, known as America's #1 Cannabis Oil Brand, has been on a path of rapid expansion since it was acquired by Curaleaf in February 2020. Select products are now available in over 950 independent dispensaries across 12 states, including Arizona, California, Colorado, Connecticut, Florida, Maryland, Michigan, Nevada, Oklahoma, Oregon, Massachusetts and Maine. The Select brand will continue to expand across the U.S. with its launch into Ohio's medical market later this month.
Curaleaf also announced the company's first retail location in the Utah market with a new pharmacy at 3633 N. Thanksgiving Way in Lehi, marking its 90th retail location nationwide.
Curaleaf UT, LLC, was awarded one of the state's 14 licenses in the state of Utah in 2019. Lehi is known as one of the state's highest growth cities and its surrounding area is home to more than 50% of the state's total qualifying patients; Utah County has 44% of the certified 10,400 patients.
The new Lehi location is strategically located directly off the I15, the state's most highly trafficked freeway, in a high retail density area which will provide optimal patient access from anywhere in the Utah County area. Curaleaf will be the first cannabis pharmacy location in the County heading south from Salt Lake on the I15.
The Company's expansion into Utah will provide more accessibility to high-quality medical cannabis products, innovative consumption formats, and leading national brands. Curaleaf is also completing construction on its state-of-the-art processing operation in North Salt Lake City, which is scheduled to open in mid-September.
"We look forward to introducing our Select and Curaleaf formulas to the patients of Utah with our new Lehi location," said Joe Bayern, President at Curaleaf. "We anticipate that demand will quickly surpass projected numbers in this market, as cannabis use continues to gain acceptance for a variety of health and wellness needs."
During the COVID-19 pandemic, cannabis businesses have been deemed an essential service in most states, including Utah. Curaleaf remains committed to serving patients and customers with the products they rely on while implementing heightened safety and hygienic measures in all its facilities.
Amyris, Inc. (NASDAQ: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that it has successfully scaled up the commercial production of Cannabigerol (CBG) leveraging its industrial fermentation process capability.
Amyris expects to deliver about one ton of high purity CBG through fermentation as an alternative to the traditional production method of extraction from the Cannabis sativa L. plant. First commercial revenue from the sale of this molecule is anticipated this year as an ingredient in applications that are excluded from Amyris's current collaboration agreements. Product margins are anticipated to operate above the current industry average realized by existing publicly traded CBD suppliers.
CBG is the precursor from which all other cannabinoids are synthesized and is often referred to as the "stem cell" of cannabinoids. CBG is a non-psychoactive cannabinoid and presents significant therapeutic potential, making it a subject of great interest for researchers and consumers alike. Amyris's fermentation process is well-positioned to result in the lowest cost CBG with higher purity (no THC), which is expected to unlock CBG's adoption.
Early testing on skin models demonstrates advantaged performance of CBG for various topical indications over CBD. Furthermore, the combination of CBG with Amyris's sugar cane-based squalene provides some of the highest efficacy results for topical applications. Early studies indicate that CBG has the potential to deliver better efficacy than CBD in about one third of current CBD topical applications.
"Amyris's biotechnology platform continues to demonstrate its capability to engineer yeast to create and produce differentiated high value products. This molecule was developed from initial target to full scale production in less than nine months," said Eduardo Alvarez, Chief Operating Officer.
"We are very excited about the disruptive nature of this molecule for potential skin care applications and through flavor and fragrance partnerships and our cosmetic distribution channels," commented John Melo, President and Chief Executive Officer. "This is the tenth product we deliver at scale through our fermentation platform, and reaffirms the continued expansion of our portfolio and our growth ambition to provide sustainably and economically produced natural ingredients."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Subscribe to:
Posts (Atom)